X hits on this document

Word document

The usefulness and use of second-generation - page 45 / 81

338 views

0 shares

0 downloads

0 comments

45 / 81

63 Daniel DG, Potkin SG, Reeves KR, , et al. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155:128-134.

64 Hwang TJ, Lin SK, Lin HN. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol. J Formos Med Assoc 2001; 100:811-816.

65Sechter D, Peuskens J, Fleurot, et al. Amisulpride vs. risperidone in chronic schizophrenia. Results of a 6-month double-blind study. Neuropsychopharmacology 2002; 27: 1071-1081.

66 Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002; 159:180-190.

67 Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000; 15:13-22.

68 Mota Neto J, Lima M, Soares B. Amisulpride for Schizophrenia. Cochrane Database Syst Rev 1999.

69 Danion JM, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group. Am J Psychiatry 1999; 156:610-616.

70 Peuskens J, Bech P, Moller HJ, , et al. Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group. Psychiatry Res 1999; 88:107-117.

71 Puech A, Fleurot O, Rein W. Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998; 98:65-72.

72 Wetzel H, Grunder G, Hillert A, , et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 1998; 137:223-232.

73 Loo H, Poirier-Littre MF, Theron M, , et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997; 170:18-22.

74Speller JC, Barnes TR, Curson DA, et al. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol. Br J Psychiatry 1997; 171:564-568.

Document info
Document views338
Page views338
Page last viewedTue Jan 24 18:37:42 UTC 2017
Pages81
Paragraphs1517
Words24865

Comments